Kindstar Globalgene Technology Inc
Company Profile
Business description
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
Contact
Biolake D2-1, 666 Gaoxin Road
East Lake High Tech Zone
Hubei Province
Wuhan
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
3,100
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
stocks
OpenAI is going public as the worst value among its peers
stocks
Wide moat healthcare leader remains undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.80 | 67.50 | 0.77% |
| CAC 40 | 8,288.20 | 88.91 | 1.08% |
| DAX 40 | 24,804.33 | 188.11 | 0.76% |
| Dow JONES (US) | 51,232.00 | 445.99 | 0.88% |
| FTSE 100 | 10,347.72 | 25.48 | -0.25% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 26,226.28 | 296.62 | 1.14% |
| Nikkei 225 | 65,416.63 | 1,392.03 | 2.17% |
| NZX 50 Index | 13,204.08 | 165.84 | 1.27% |
| S&P 500 | 7,475.98 | 70.25 | 0.95% |
| S&P/ASX 200 | 8,604.20 | 70.70 | 0.83% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |